// App-Quantinova.ai

: Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza).

Researchers

Presenter

  • John Silberstein

Principal Investigators

  • Brandon Luber

  • Hao Wang

  • Changxue Lu

  • Yan Chen

  • Yezi Zhu

  • Maritza N. Taylor

  • Michael Anthony Carducci

  • Mario A. Eisenberger

  • Jun Luo

  • Emmanuel S. Antonarakis

Medical Centers

  • The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved